Doxorubicin

多柔比星

Also known as: Adriamycin, Hydroxydaunorubicin, 14-Hydroxydaunomycin, Doxorubicina, Doxorubicinum, Adriblastina

Doxorubicin (CAS 23214-92-8) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C27H29NO11 and a molecular weight of 543.52 g/mol. It is also known as Adriamycin, Hydroxydaunorubicin and 14-Hydroxydaunomycin. Key properties include a melting point of 205ºC, a density of 1.61 g/cm3 and a flash point of 443.8ºC. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 23214-92-8
Jingsj CID: J-1974717-6
Molecular Formula: C₂₇H₂₉NO₁₁
Chinese Name: 多柔比星
Molecular Weight: 543.52 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

No offers for this compound yet.

Request a quote

Physicochemical Properties

Melting Point	205ºC
Density	1.61 g/cm3
Flash Point	443.8ºC
PSA	206.07000
LogP	1.50360
Vapor Pressure	9.64E-28mmHg at 25°C
Refractive Index	1.709
Additional Property	Soluble

Activity & Biological Data

Target	Topoisomerase II
Additional Information	[1]. Nitiss JL, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50. [2]. Sadeghi-Aliabadi H, et al. Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells. Res Pharm Sci. 2010 Jul;5(2):127-33. [3]. El-Zawahry A, et al. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancerxenografts. BMC Cancer. 2005 Jan 7;5:2. [4]. Hayward R, et al. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007 Jul;46(4):20-32. [5]. Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108. [6]. Majumder S, et al. Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease. J Clin Invest. 2018 Jan 2;128(1):483-499.

Target

Topoisomerase II

Additional Information

[1]. Nitiss JL, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50. [2]. Sadeghi-Aliabadi H, et al. Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells. Res Pharm Sci. 2010 Jul;5(2):127-33. [3]. El-Zawahry A, et al. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancerxenografts. BMC Cancer. 2005 Jan 7;5:2. [4]. Hayward R, et al. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007 Jul;46(4):20-32. [5]. Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108. [6]. Majumder S, et al. Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease. J Clin Invest. 2018 Jan 2;128(1):483-499.

Frequently Asked Questions

What is the CAS number of Doxorubicin?

The CAS number of Doxorubicin is 23214-92-8.

What are the molecular formula and molecular weight of Doxorubicin?

Doxorubicin has molecular formula C27H29NO11 and molecular weight 543.52 g/mol.

What are the upstream and downstream products of Doxorubicin?

For Doxorubicin, Upstream Products: Doxorubicin hydrochloride; Downstream Products: Doxorubicinone.

Data compiled from public chemical databases and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Doxorubicin (CAS 23214-92-8)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1974717-6 (accessed 2026-10-28).

Data for reference only; verify specifications, grades and regulatory status with suppliers before purchase.